XFOR SEC Filing News — X4 Pharmaceuticals, Inc.

Latest SEC filings for X4 Pharmaceuticals, Inc. (XFOR) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-08.

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufac…
Sector: Healthcare Industry: Biotechnology Market Cap: $272.7M CIK: 1501697
20
Total Filings
0
Bullish Classifications
5
Bearish Classifications
7
Insider Transactions
6
Material Events (8-K)
3
Periodic Reports
Rule-based classifications for XFOR currently lean bearish. Of the 20 filing records displayed, 5 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.
XFOR Filing Activity Snapshot 2026-01-07 — 2026-10-08
Insider Transactions (Form 4)
0 buys vs 5 sells
Net insider selling in this period — insiders sell for many reasons beyond conviction.
Largest Form 144 Filing
$216.1K
Adam Craig · 2026-08-13
47,436 shares · Form 144
Form 144 Notices
4
Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.
Insider Transactions 7 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 7 filings in this group are Form 4s for X4 Pharmaceuticals, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 7 insider filings shown, the breakdown is 5 open-market sale and 2 compensation award. 5 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Open-market sale ×5
The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Compensation award ×2
Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Form 4 Open-market sale Insider Selling 2026-10-05

XFOR insider KIRSKE DAVID (Chief Financial Officer) sold 11,767 shares (~$33.7K)

KIRSKE DAVID, listed as Chief Financial Officer at X4 Pharmaceuticals, Inc, reported an open-market sale of 11,767 XFOR shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 11,767 $2.86 $33.7K
Filing: Form 4 (Insider Transaction) Insider: KIRSKE DAVID (Chief Financial Officer) Shares: 11,767 Est. Value: $33.7K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-13

XFOR insider Volpone John (President) sold 24,576 shares (~$109.2K)

Volpone John, listed as President at X4 Pharmaceuticals, Inc, reported an open-market sale of 24,576 XFOR shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 24,576 $4.44 $109.2K
Filing: Form 4 (Insider Transaction) Insider: Volpone John (President) Shares: 24,576 Est. Value: $109.2K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-13

XFOR insider Craig Adam R (Director, Executive Chairman) sold 47,436 shares (~$210.8K)

Craig Adam R, listed as Director, Executive Chairman at X4 Pharmaceuticals, Inc, reported an open-market sale of 47,436 XFOR shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 47,436 $4.44 $210.8K
Filing: Form 4 (Insider Transaction) Insider: Craig Adam R (Director, Executive Chairman) Shares: 47,436 Est. Value: $210.8K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-07-01

XFOR insider KIRSKE DAVID (Chief Financial Officer) sold 8,543 shares (~$36.4K)

KIRSKE DAVID, listed as Chief Financial Officer at X4 Pharmaceuticals, Inc, reported an open-market sale of 8,543 XFOR shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 8,543 $4.26 $36.4K
Filing: Form 4 (Insider Transaction) Insider: KIRSKE DAVID (Chief Financial Officer) Shares: 8,543 Est. Value: $36.4K
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-07-01

XFOR insider Form 4 filed for equity award, exercise, or tax withholding

Gold Kelly (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Stock Option (right to buy) 110,000 — —
Filing: Form 4 (Insider Transaction) Insider: Gold Kelly (Director)
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-05-13

XFOR insider KIRSKE DAVID (Chief Financial Officer) sold 16,961 shares (~$72.8K)

KIRSKE DAVID, listed as Chief Financial Officer at X4 Pharmaceuticals, Inc, reported an open-market sale of 16,961 XFOR shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 16,961 $4.29 $72.8K
Filing: Form 4 (Insider Transaction) Insider: KIRSKE DAVID (Chief Financial Officer) Shares: 16,961 Est. Value: $72.8K
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-01-07

XFOR insider Form 4 filed for equity award, exercise, or tax withholding

Bridger Gary (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Stock Option (right to buy) 110,000 — —
Filing: Form 4 (Insider Transaction) Insider: Bridger Gary (Director)
View on SEC EDGAR → Open Filing Document →
Proposed Insider Sales 4 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. X4 Pharmaceuticals, Inc. has 4 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-10-01

XFOR Form 144 filed for proposed insider sale by David Kirske (11,767 shares) ~$33.7K

David Kirske filed a Form 144 with the SEC indicating intent to sell XFOR (X4 Pharmaceuticals, Inc) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: David Kirske Shares: 11,767 Est. Value: $33.7K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-08-13

XFOR Form 144 filed for proposed insider sale by John Volpone (24,576 shares) ~$111.9K

John Volpone filed a Form 144 with the SEC indicating intent to sell XFOR (X4 Pharmaceuticals, Inc) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: John Volpone Shares: 24,576 Est. Value: $111.9K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-08-13

XFOR Form 144 filed for proposed insider sale by Adam Craig (47,436 shares) ~$216.1K

Adam Craig filed a Form 144 with the SEC indicating intent to sell XFOR (X4 Pharmaceuticals, Inc) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Adam Craig Shares: 47,436 Est. Value: $216.1K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-05-12

XFOR Form 144 filed for proposed insider sale by David Kirske (16,961 shares) ~$72.8K

David Kirske filed a Form 144 with the SEC indicating intent to sell XFOR (X4 Pharmaceuticals, Inc) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: David Kirske Shares: 16,961 Est. Value: $72.8K
View on SEC EDGAR → Open Filing Document →
Material Events 6 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 6 in this period for X4 Pharmaceuticals, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-10-08

XFOR filed 8-K — material company event

X4 Pharmaceuticals, Inc filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-09-09

XFOR filed 8-K — material company event

X4 Pharmaceuticals, Inc filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-09-08

XFOR filed 8-K — material company event

X4 Pharmaceuticals, Inc filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-07-01

XFOR filed 8-K — material company event

X4 Pharmaceuticals, Inc filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K/A Amended Material Company Update 2026-05-13

XFOR filed amended 8-K — material company event

X4 Pharmaceuticals, Inc filed an amended 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K/A (Material Event Amendment)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-05-12

XFOR filed 8-K — material company event

X4 Pharmaceuticals, Inc filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Periodic Reports 3 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 annual report (10-K) and 2 quarterly reports (10-Q) for X4 Pharmaceuticals, Inc.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-08-06

XFOR filed Quarterly Report (10-Q)

X4 Pharmaceuticals, Inc filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)
View on SEC EDGAR → Open Filing Document →
Form 10-Q Quarterly Report 2026-05-06

XFOR filed Quarterly Report (10-Q)

X4 Pharmaceuticals, Inc filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)
View on SEC EDGAR → Open Filing Document →
Form 10-K Annual Report 2026-03-17

XFOR filed Annual Report (10-K)

X4 Pharmaceuticals, Inc filed its annual report with the SEC. This report includes audited financial statements, business overview, risk factors, and management discussion.

Filing: 10-K (Annual Report)
View on SEC EDGAR → Open Filing Document →

How we classify X4 Pharmaceuticals, Inc.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on XFOR. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — XFOR SEC Filings

More Tools for XFOR

XFOR Full Stock Analysis XFOR Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper XFOR analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the XFOR stock analysis page.

XFOR Full Analysis
Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.
Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer